Tortugas Debuts with $106M and Brain Drugs from Hansoh, Eisai

Tortugas Neuroscience Launches with $106M and Licensed Brain Drugs

Tortugas Neuroscience, a new biotech led by former Sage Therapeutics executives Jeff Jonas and Al Robichaud, has launched with $106 million in funding. The Framingham, Massachusetts-based company secured a seed round led by Cure Ventures and a Series A round involving Cure, Column Group, and AN Venture Partners. Tortugas debuts with a portfolio of four experimental small molecule medicines, licensed from Eisai and Jiangsu Hansoh Pharmaceutical Group, which are already in clinical testing for various central nervous system disorders including schizophrenia, tinnitus, and focal epilepsy. The financing will support the completion of Phase 2 studies for two of these programs, with a long-term goal of developing in-house drugs.

• Tortugas Neuroscience secured $106 million through a seed round led by Cure Ventures and a Series A round with additional investment from Column Group and AN Venture Partners. This substantial initial funding provides a strong financial foundation for the startup's clinical development plans and enables it to advance its early-stage pipeline.
• The company's initial portfolio comprises four experimental small molecule medicines, all licensed from Japanese drugmaker Eisai and Shanghai-based Jiangsu Hansoh Pharmaceutical Group. These assets are already in clinical testing, offering "derisked mechanisms of action" and a "stable clinical foundation" to accelerate value creation and reduce initial development risks.
• Tortugas Neuroscience is uniquely focused on central nervous system disorders, including schizophrenia, tinnitus, and focal epilepsy. This strategic therapeutic area focus distinguishes it from many other venture-backed biotechs that often target cancer, immune, or metabolic diseases, addressing a significant unmet medical need in neurology.
• Led by former Sage Therapeutics executives Jeff Jonas (CEO) and Al Robichaud (partner at Cure Ventures), Tortugas benefits from seasoned leadership with a track record of taking a company public and bringing drugs to market. The initial strategy involves advancing two programs through Phase 2 studies with the current funding, with plans for in-house drug development later.

Why Tortugas' Derisked Approach Fits the Evolving CNS Landscape

The central nervous system treatment landscape has undergone significant transformation over the past five years, driven by technological advances and novel therapeutic approaches. Artificial intelligence-driven PET-MRI multimodal imaging has emerged as a cornerstone technology, fundamentally reshaping diagnostic and therapeutic paradigms for neurodegenerative diseases including Alzheimer's and Parkinson's disease. This AI integration extends beyond imaging, with machine learning algorithms successfully identifying responder subgroups in clinical trials, as demonstrated in autism treatment studies where the Q-Finder algorithm identified up to 40% of participants as potential responders to Bumetanide therapy, despite overall phase 3 trial failures.

Drug delivery innovations have marked another pivotal evolution, with phospholipid nanocomplexes (PNCs) establishing themselves as next-generation neurotherapeutics that utilize natural blood-brain barrier transport pathways. These systems enable receptor-mediated transcytosis and lipid raft-mediated transport, delivering neurotrophic factors, antioxidants, and gene-silencing therapies with significantly improved neuronal survival and cognitive outcomes across Alzheimer's disease, Parkinson's disease, glioblastoma, and multiple sclerosis. Concurrently, diverse mechanistic approaches have expanded the therapeutic arsenal, including histamine H3 receptor antagonists for schizophrenia-related cognitive impairments, α7 nicotinic acetylcholine receptor modulators leveraging cholinergic anti-inflammatory pathways, and GLP-1 receptor agonists demonstrating neuroprotective properties beyond their established metabolic effects.

The clinical trial landscape has evolved to address longstanding participation barriers, with systematic analyses of over 5,000 participants identifying key enablers including strengthened patient-physician relationships (70% of respondents), enhanced study information availability (67%), and modified control arm approaches (53%). These insights have informed more patient-centric trial designs while addressing the persistent challenges of translating promising preclinical findings to clinical success. Despite technological advances, fundamental hurdles remain including scalability of novel delivery systems, long-term safety profiles of innovative therapeutics, and the inherent complexity of CNS microenvironments that continue to limit clinical translation of mechanistically diverse therapeutic approaches.

Addressing Key Challenges in Current CNS Treatment

Current treatment approaches for Central Nervous System disorders face multifaceted challenges that significantly impact therapeutic outcomes and drug development. These limitations span from physiological barriers to drug delivery, disease-specific complexities, and translational research gaps. The convergence of these factors creates substantial obstacles for achieving optimal therapeutic efficacy in CNS therapeutics.

• Blood-brain barrier penetration represents the primary pharmaceutical challenge, as this tightly regulated barrier restricts therapeutic access to cerebral parenchyma, limiting passage to only molecules <400 Da with lipophilic properties and resulting in poor brain bioavailability for most conventional drugs

• Suboptimal therapeutic efficacy characterizes current CNS treatments, with conventional therapeutics remaining critically below optimal therapeutic levels due to extensive first-pass metabolism, short elimination half-lives, and systemic adverse effects that limit dosing potential

• Neurodegenerative disease complexity poses unique treatment obstacles, including unknown etiology, unfavorable prognosis, insidious onset with atypical early manifestations that impede early diagnosis, and hallmark protein aggregate lesions that resist current therapeutic approaches

• Drug development pipeline gaps persist despite enormous market demand, particularly the absence of disease-modifying drugs for neurodegenerative diseases, which represent the sixth leading cause of death in the US, while complete remission for conditions like Multiple Sclerosis remains elusive despite numerous approved therapeutics

• Emerging delivery system limitations include predominantly preclinical evidence for novel approaches like intranasal nanocarrier systems, with significant variability in study design and pharmacokinetic reporting, plus formulation challenges including mucociliary clearance, nasal irritation, and burst drug release patterns

• Research infrastructure deficits compound treatment challenges, with brain research funding in Europe representing only 1% of the 400 billion euro annual cost of brain disorders, insufficient understanding of neurological disorder mechanisms, and organizational obstacles within academic drug development programs

Tortugas' Pipeline: Positioning Against Current CNS Standard of Care

Current standard of care treatments for CNS disorders remain largely palliative, focusing on symptom management rather than addressing underlying disease mechanisms. For conditions such as Alzheimer's disease and multiple sclerosis, existing therapies primarily provide symptomatic relief without halting disease progression through conventional pharmacologic approaches. This treatment gap has prompted extensive investigation into alternative therapeutic strategies, including natural compounds, novel delivery methods, and repurposed medications such as metformin, which is currently being evaluated across multiple CNS conditions including multiple sclerosis, schizophrenia, and fragile X syndrome.

Stroke prevention guidelines have evolved significantly, particularly for women, with the 2024 American Heart Association/American Stroke Association introducing class I recommendations for screening adverse pregnancy outcomes as part of comprehensive stroke prevention. For midlife women aged 40-65, current standards emphasize incorporating reproductive history, menopausal transition status, and novel biomarkers alongside traditional risk factors. Evidence now supports personalized, timing-based approaches for menopause hormone therapy, resolving previous controversies through data demonstrating that inflammatory and lipid biomarkers measured in midlife can predict stroke risk years in advance.

Emerging diagnostic and monitoring approaches are reshaping CNS care standards, particularly in acute settings. Point-of-care EEG implementation in pediatric emergency departments has demonstrated significant clinical utility, influencing 60% of clinical decisions through rapid identification of seizure activity and nonconvulsive status epilepticus. For inflammatory demyelinating diseases, current guidelines increasingly incorporate functional outcomes such as the Timed 25-Foot Walk Test alongside advanced biomarkers including neurofilament light chain and glial fibrillary acidic protein. Additionally, evidence supports integrating lifestyle interventions, particularly Mediterranean and MIND diets combined with structured physical activity programs, as complementary strategies to disease-modifying treatments from early disease stages.

Former Sage Leaders Chart New Course in CNS Drug Development

The recent launch of Tortugas Neuroscience, backed by $106 million in funding and led by former Sage Therapeutics executives Jeff Jonas and Al Robichaud, signals a strategic re-entry into the challenging yet high-potential landscape of central nervous system (CNS) drug development. This new biotech is not starting from scratch; it has licensed four experimental small molecule medicines already in clinical testing for various CNS disorders, including schizophrenia, tinnitus, and focal epilepsy.

The leadership's pedigree is particularly noteworthy. At Sage Therapeutics, Jonas and Robichaud were instrumental in advancing compounds like SAGE-217, a GABA type A receptor positive allosteric modulator that demonstrated efficacy in major depressive disorder, and SAGE-718, an NMDAR positive allosteric modulator for cognitive impairment. This background provides Tortugas with a deep understanding of the complexities of CNS targets and the rigorous demands of clinical development in this space.

Tortugas' strategy to acquire assets already in Phase 2 is a calculated move to accelerate its pipeline and potentially de-risk initial investments. This approach allows the company to leverage existing clinical data and focus its substantial funding on advancing these programs through critical mid-stage trials. However, the inherent difficulties of CNS development cannot be overstated. Even with experienced leadership and promising mechanisms, late-stage hurdles can emerge, as illustrated by the termination of Sage's SAGE-718 Phase 3 PURVIEW study. This serves as a stark reminder that efficacy and safety challenges can arise even for compounds that show promise in earlier phases.

Furthermore, the market for CNS disorders, particularly schizophrenia, presents significant access and reimbursement challenges. Formulary decision-makers grapple with high pharmacy and medical costs, medication nonadherence, and frequent hospitalizations. Any new therapy, regardless of its clinical benefit, will need to demonstrate compelling value to overcome utilization management policies and achieve broad patient access. Tortugas' long-term ambition to develop in-house drugs alongside its licensed portfolio suggests a comprehensive strategy to build a sustainable presence, blending the speed of external acquisition with the long-term value of proprietary innovation. The success of this venture will hinge on its ability to navigate these scientific, clinical, and market complexities effectively.